Panel to Discuss Bristol-Myers Squibb Hepatitis B NDAs
01/28/2005
Federal Register Notice: FDA’s Antiviral Drugs Advisory Committee will meet 3/11, from 8 a.m. to 5 p.m. at the Hilton Washington DC North/Gaithersburg, Gaithersburg, MD. The committee will discuss two Bristol-Myers Squibb Co. NDAs for entecavir tablets and entecavir oral solution, proposed for treating patients with chronic hepatitis B infection. Contact Anuja Patel, (301) 827-7001. To view this notice, click here.
